fluoxetine has been researched along with Aura in 37 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nineteen mentally retarded inpatients with epilepsy and a history of current or recent aggressive behavior were treated with 20 mg of fluoxetine daily." | 9.08 | Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy. ( Ciani, N; Nuccetelli, F; Pasini, A; Troisi, A; Vicario, E, 1995) |
| "Serotonin and fluoxetine, but not sumatriptan, alleviated PTZ-induced seizures by prolonging onset times of myoclonic-jerk and generalized tonic-clonic seizures." | 8.12 | Endogenous and exogenous serotonin, but not sumatriptan, ameliorate seizures and neuroinflammation in the pentylenetetrazole-induced seizure model in rats. ( Kilinc, E; Kılınc, YB; Torun, IE, 2022) |
| " The main objective of this work was to investigate the effect of the selective 5-HT selective reuptake inhibitor (SSRI) fluoxetine administered subacutely (10mg/kg/day×7 days) on the eventual metabolic impairment induced by the lithium-pilocarpine model of epilepsy in rats." | 7.81 | Subacute administration of fluoxetine prevents short-term brain hypometabolism and reduces brain damage markers induced by the lithium-pilocarpine model of epilepsy in rats. ( Bascuñana, P; de Cristóbal, J; Delgado, M; Fernández de la Rosa, R; García-García, L; Pozo, MA; Shiha, AA, 2015) |
| "Status epilepticus was induced in the rats by administration of pilocarpine 350 mg/kg i." | 7.77 | Piperine protects epilepsy associated depression: a study on role of monoamines. ( Nayak, S; Pal, A; Sahu, PK; Swain, T, 2011) |
| "Fluoxetine (20 mg/kg) and TFMPP (5 mg/kg) were administered to rats with pilocarpine-induced epilepsy." | 7.71 | Effects of fluoxetine and TFMPP on spontaneous seizures in rats with pilocarpine-induced epilepsy. ( Dudek, FE; Hernandez, EJ; Williams, PA, 2002) |
| "This study was designed to demonstrate a role of serotonin in the anticonvulsant effect of fluoxetine, a serotonin reuptake inhibitor, in genetically epilepsy-prone rats." | 7.69 | Role of serotonin in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. ( Cheong, JH; Dailey, JW; Jobe, PC; Ko, KH; Yan, QS, 1994) |
| "To test the hypothesis that fluoxetine may be a useful adjunct to antiepileptic therapy, we treated with fluoxetine (20-40 mg/day) nine patients suffering from medically intractable epilepsy with daily seizures." | 7.69 | Lack of potentiation of anticonvulsant effect by fluoxetine in drug-resistant epilepsy. ( Baldinetti, F; Diomedi, M; Gigli, GL; Girolami, E; Marciani, MG; Pasini, A; Troisi, A, 1994) |
| "Fluoxetine, an antidepressant and inhibitor of serotonin reuptake, was evaluated as an anticonvulsant in genetically epilepsy-prone rats (GEPRs) because seizure predisposition in GEPRs is partially dependent on deficits in brain serotonin." | 7.68 | Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats. ( Burger, RL; Dailey, JW; Jobe, PC; Mishra, PK; Yan, QS, 1992) |
| "Furthermore, children with highly refractory epilepsy are at particular risk of sudden unexpected death." | 5.62 | Fluoxetine as adjunctive therapy in pediatric patients with refractory epilepsy: A retrospective analysis. ( Desnous, B; Milh, M; Neveu, J; Villeneuve, N, 2021) |
| "In this sample of children and adolescents with epilepsy and depressive disorders, we observed that SSRIs are a good therapeutic option, considering their efficacy in remission of depressive symptoms, their few adverse effects, and their maintenance of satisfactory seizure control." | 5.34 | Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. ( Kuczynski, E; Thomé-Souza, MS; Valente, KD, 2007) |
| "Nineteen mentally retarded inpatients with epilepsy and a history of current or recent aggressive behavior were treated with 20 mg of fluoxetine daily." | 5.08 | Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy. ( Ciani, N; Nuccetelli, F; Pasini, A; Troisi, A; Vicario, E, 1995) |
| "Pregabalin (PGB) is used in drug-resistant epilepsy." | 4.31 | The investigation of antidepressant and anxiolytic effects of pregabalin and its mechanisms of action in rats. ( Aydın, Ş; Çivgin, ME; Dinçer Öner, S; Kılıç Tatlıcı, C; Kılıç, FS; Yazıcı, ZG; Yıldırım, C, 2023) |
| "Serotonin and fluoxetine, but not sumatriptan, alleviated PTZ-induced seizures by prolonging onset times of myoclonic-jerk and generalized tonic-clonic seizures." | 4.12 | Endogenous and exogenous serotonin, but not sumatriptan, ameliorate seizures and neuroinflammation in the pentylenetetrazole-induced seizure model in rats. ( Kilinc, E; Kılınc, YB; Torun, IE, 2022) |
| " The main objective of this work was to investigate the effect of the selective 5-HT selective reuptake inhibitor (SSRI) fluoxetine administered subacutely (10mg/kg/day×7 days) on the eventual metabolic impairment induced by the lithium-pilocarpine model of epilepsy in rats." | 3.81 | Subacute administration of fluoxetine prevents short-term brain hypometabolism and reduces brain damage markers induced by the lithium-pilocarpine model of epilepsy in rats. ( Bascuñana, P; de Cristóbal, J; Delgado, M; Fernández de la Rosa, R; García-García, L; Pozo, MA; Shiha, AA, 2015) |
| "Status epilepticus was induced in the rats by administration of pilocarpine 350 mg/kg i." | 3.77 | Piperine protects epilepsy associated depression: a study on role of monoamines. ( Nayak, S; Pal, A; Sahu, PK; Swain, T, 2011) |
| " In this study the anticonvulsant actions of norfluoxetine and fluoxetine were studied and compared to those of phenytoin and clonazepam in pentylenetetrazol-induced mouse epilepsy models." | 3.73 | Norfluoxetine and fluoxetine have similar anticonvulsant and Ca2+ channel blocking potencies. ( Harasztosi, C; Kecskeméti, V; Nánási, PP; Pál, B; Riba, P; Rusznák, Z; Szûcs, G; Wagner, R, 2005) |
| "Fluoxetine (20 mg/kg) and TFMPP (5 mg/kg) were administered to rats with pilocarpine-induced epilepsy." | 3.71 | Effects of fluoxetine and TFMPP on spontaneous seizures in rats with pilocarpine-induced epilepsy. ( Dudek, FE; Hernandez, EJ; Williams, PA, 2002) |
| "This study was designed to demonstrate a role of serotonin in the anticonvulsant effect of fluoxetine, a serotonin reuptake inhibitor, in genetically epilepsy-prone rats." | 3.69 | Role of serotonin in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. ( Cheong, JH; Dailey, JW; Jobe, PC; Ko, KH; Yan, QS, 1994) |
| "To test the hypothesis that fluoxetine may be a useful adjunct to antiepileptic therapy, we treated with fluoxetine (20-40 mg/day) nine patients suffering from medically intractable epilepsy with daily seizures." | 3.69 | Lack of potentiation of anticonvulsant effect by fluoxetine in drug-resistant epilepsy. ( Baldinetti, F; Diomedi, M; Gigli, GL; Girolami, E; Marciani, MG; Pasini, A; Troisi, A, 1994) |
| "Fluoxetine, an antidepressant and inhibitor of serotonin reuptake, was evaluated as an anticonvulsant in genetically epilepsy-prone rats (GEPRs) because seizure predisposition in GEPRs is partially dependent on deficits in brain serotonin." | 3.68 | Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats. ( Burger, RL; Dailey, JW; Jobe, PC; Mishra, PK; Yan, QS, 1992) |
| "Furthermore, children with highly refractory epilepsy are at particular risk of sudden unexpected death." | 1.62 | Fluoxetine as adjunctive therapy in pediatric patients with refractory epilepsy: A retrospective analysis. ( Desnous, B; Milh, M; Neveu, J; Villeneuve, N, 2021) |
| "Depression is the most common psychiatric comorbidity of epilepsy." | 1.62 | Chronically altered NMDAR signaling in epilepsy mediates comorbid depression. ( Dehpour, AR; Hemmati, S; Mohammadi, S; Sadeghi, MA; Vafaei, A; Yousefi-Manesh, H; Zare, M, 2021) |
| "In this sample of children and adolescents with epilepsy and depressive disorders, we observed that SSRIs are a good therapeutic option, considering their efficacy in remission of depressive symptoms, their few adverse effects, and their maintenance of satisfactory seizure control." | 1.34 | Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. ( Kuczynski, E; Thomé-Souza, MS; Valente, KD, 2007) |
| "When fluoxetine (3 microM) was applied first neither nifedipine nor omega-conotoxin attenuated the remaining component of the HVA current." | 1.31 | Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells. ( Deák, F; Lasztóczi, B; Pacher, P; Petheö, GL; Spät, A, 2000) |
| "With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy." | 1.30 | Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. ( Baldessarini, RJ; Bodkin, JA; Gardner, DM; Lasser, RA; Wines, JD, 1997) |
| "Pretreatment with prazosin (1 microgram/side) significantly diminished the anticonvulsant effectiveness of methoxamine and nisoxetine while prazosin, by itself, had no effects on the seizure intensity." | 1.30 | Anticonvulsant effect of enhancement of noradrenergic transmission in the superior colliculus in genetically epilepsy-prone rats (GEPRs): a microinjection study. ( Dailey, JW; Jobe, PC; Steenbergen, JL; Yan, QS, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (43.24) | 18.2507 |
| 2000's | 7 (18.92) | 29.6817 |
| 2010's | 10 (27.03) | 24.3611 |
| 2020's | 4 (10.81) | 2.80 |
| Authors | Studies |
|---|---|
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Neveu, J | 1 |
| Villeneuve, N | 1 |
| Milh, M | 1 |
| Desnous, B | 1 |
| Torun, IE | 1 |
| Kılınc, YB | 1 |
| Kilinc, E | 1 |
| Aydın, Ş | 1 |
| Kılıç Tatlıcı, C | 1 |
| Çivgin, ME | 1 |
| Yazıcı, ZG | 1 |
| Yıldırım, C | 1 |
| Dinçer Öner, S | 1 |
| Kılıç, FS | 1 |
| Sadeghi, MA | 1 |
| Hemmati, S | 1 |
| Mohammadi, S | 1 |
| Yousefi-Manesh, H | 1 |
| Vafaei, A | 1 |
| Zare, M | 1 |
| Dehpour, AR | 1 |
| Lovick, T | 1 |
| Cardamone, L | 1 |
| Salzberg, MR | 1 |
| Koe, AS | 1 |
| Ozturk, E | 1 |
| O'Brien, TJ | 1 |
| Jones, NC | 1 |
| Puzerey, PA | 1 |
| Decker, MJ | 1 |
| Galán, RF | 1 |
| Shiha, AA | 1 |
| de Cristóbal, J | 1 |
| Delgado, M | 1 |
| Fernández de la Rosa, R | 1 |
| Bascuñana, P | 1 |
| Pozo, MA | 1 |
| García-García, L | 1 |
| Zeng, C | 1 |
| Long, X | 1 |
| Cotten, JF | 1 |
| Forman, SA | 1 |
| Solt, K | 1 |
| Faingold, CL | 1 |
| Feng, HJ | 1 |
| Lance, S | 1 |
| Ternouth, I | 1 |
| Choi, HC | 1 |
| Kim, YI | 1 |
| Song, HK | 1 |
| Kim, JE | 1 |
| Kim, DS | 1 |
| Kang, TC | 1 |
| Pal, A | 1 |
| Nayak, S | 1 |
| Sahu, PK | 1 |
| Swain, T | 1 |
| Pineda, EA | 1 |
| Hensler, JG | 1 |
| Sankar, R | 1 |
| Shin, D | 1 |
| Burke, TF | 1 |
| Mazarati, AM | 1 |
| Hernandez, EJ | 1 |
| Williams, PA | 1 |
| Dudek, FE | 1 |
| Kecskeméti, V | 1 |
| Rusznák, Z | 1 |
| Riba, P | 1 |
| Pál, B | 1 |
| Wagner, R | 1 |
| Harasztosi, C | 1 |
| Nánási, PP | 1 |
| Szûcs, G | 1 |
| Albano, C | 3 |
| Cupello, A | 1 |
| Mainardi, P | 3 |
| Scarrone, S | 1 |
| Favale, E | 2 |
| Thomé-Souza, MS | 1 |
| Kuczynski, E | 1 |
| Valente, KD | 1 |
| Merrill, MA | 1 |
| Clough, RW | 1 |
| Dailey, JW | 5 |
| Jobe, PC | 5 |
| Browning, RA | 1 |
| Rubino, V | 2 |
| Lunardi, G | 2 |
| Yan, QS | 4 |
| Cheong, JH | 1 |
| Ko, KH | 1 |
| Troisi, A | 3 |
| Vicario, E | 1 |
| Nuccetelli, F | 1 |
| Ciani, N | 1 |
| Pasini, A | 2 |
| Gigli, GL | 1 |
| Diomedi, M | 1 |
| Baldinetti, F | 1 |
| Marciani, MG | 1 |
| Girolami, E | 1 |
| Darley, J | 1 |
| Friedman, EH | 1 |
| Fracassi, M | 1 |
| Pioli, F | 1 |
| Cultrera, S | 1 |
| Bodkin, JA | 1 |
| Lasser, RA | 1 |
| Wines, JD | 1 |
| Gardner, DM | 1 |
| Baldessarini, RJ | 1 |
| Steenbergen, JL | 1 |
| Lu, KT | 1 |
| Gean, PW | 1 |
| Deák, F | 1 |
| Lasztóczi, B | 1 |
| Pacher, P | 1 |
| Petheö, GL | 1 |
| Spät, A | 1 |
| Romerio, SC | 1 |
| Radanowicz, V | 1 |
| Schlienger, RG | 1 |
| Droulers, A | 1 |
| Bodak, N | 1 |
| Oudjhani, M | 1 |
| Lefevre des Noettes, V | 1 |
| Bodak, A | 1 |
| Jalil, P | 1 |
| Mishra, PK | 1 |
| Burger, RL | 1 |
| Thompson, PM | 1 |
| Zebrowski, G | 1 |
| Neuman, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640] | Phase 1/Phase 2 | 520 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | ||
| Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979] | Phase 4 | 35 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline Mean MDAR score | Week 4 Mean MDAR score | Change from BL in mean MDAR score | |
| Lisdexamfetamine Dimesylate (Vyvanse) | 13.46 | 6.36 | -7.08 |
| Placebo Adjunct | 12.57 | 9.08 | -3.49 |
1 review available for fluoxetine and Aura
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
1 trial available for fluoxetine and Aura
| Article | Year |
|---|---|
Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy.
Topics: Adult; Aggression; Epilepsy; Female; Fluoxetine; Humans; Individuality; Intellectual Disability; Mal | 1995 |
35 other studies available for fluoxetine and Aura
| Article | Year |
|---|---|
Fluoxetine as adjunctive therapy in pediatric patients with refractory epilepsy: A retrospective analysis.
Topics: Adult; Anticonvulsants; Child; Drug Resistant Epilepsy; Epilepsy; Fluoxetine; Humans; Retrospective | 2021 |
Endogenous and exogenous serotonin, but not sumatriptan, ameliorate seizures and neuroinflammation in the pentylenetetrazole-induced seizure model in rats.
Topics: Animals; Anticonvulsants; Epilepsy; Fluoxetine; Humans; Interleukin-6; Male; Neuroinflammatory Disea | 2022 |
The investigation of antidepressant and anxiolytic effects of pregabalin and its mechanisms of action in rats.
Topics: Amitriptyline; Animals; Anti-Anxiety Agents; Antidepressive Agents; Epilepsy; Fluoxetine; Humans; Ke | 2023 |
Chronically altered NMDAR signaling in epilepsy mediates comorbid depression.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Depression; Epilepsy; Fluoxetine; Indazoles; Male; | 2021 |
SSRIs and the female brain--potential for utilizing steroid-stimulating properties to treat menstrual cycle-linked dysphorias.
Topics: Animals; Brain; Dose-Response Relationship, Drug; Epilepsy; Female; Fluoxetine; GABAergic Neurons; H | 2013 |
Chronic antidepressant treatment accelerates kindling epileptogenesis in rats.
Topics: Amygdala; Analysis of Variance; Animals; Antidepressive Agents; Drug Delivery Systems; Electric Stim | 2014 |
Elevated serotonergic signaling amplifies synaptic noise and facilitates the emergence of epileptiform network oscillations.
Topics: Animals; Computer Simulation; Electrodes, Implanted; Electroencephalography; Epilepsy; Excitatory Po | 2014 |
Subacute administration of fluoxetine prevents short-term brain hypometabolism and reduces brain damage markers induced by the lithium-pilocarpine model of epilepsy in rats.
Topics: Animals; Apoptosis; Astrocytes; Brain; Caspase 3; Disease Models, Animal; Epilepsy; Fluoxetine; Gluc | 2015 |
Fluoxetine prevents respiratory arrest without enhancing ventilation in DBA/1 mice.
Topics: Animals; Death, Sudden; Disease Models, Animal; Epilepsy; Fluoxetine; Mice; Mice, Inbred DBA; Pulmon | 2015 |
Fluoxetine-induced phenytoin toxicity: a clinical reminder about the perils of polypharmacy.
Topics: Antidepressive Agents, Second-Generation; Drug Interactions; Epilepsy; Female; Fluoxetine; Humans; M | 2015 |
Effects of selective serotonin reuptake inhibitors on GABAergic inhibition in the hippocampus of normal and pilocarpine induced epileptic rats.
Topics: Analysis of Variance; Animals; Citalopram; Electroencephalography; Epilepsy; Fluoxetine; gamma-Amino | 2010 |
Piperine protects epilepsy associated depression: a study on role of monoamines.
Topics: Alkaloids; Anhedonia; Animals; Anticonvulsants; Behavior, Animal; Benzodioxoles; Biogenic Monoamines | 2011 |
Interleukin-1β causes fluoxetine resistance in an animal model of epilepsy-associated depression.
Topics: Animals; Antidepressive Agents, Second-Generation; Depression; Disease Models, Animal; Drug Resistan | 2012 |
Effects of fluoxetine and TFMPP on spontaneous seizures in rats with pilocarpine-induced epilepsy.
Topics: Animals; Convulsants; Epilepsy; Fluoxetine; Male; Pilocarpine; Piperazines; Rats; Rats, Sprague-Dawl | 2002 |
Norfluoxetine and fluoxetine have similar anticonvulsant and Ca2+ channel blocking potencies.
Topics: Animals; Anticonvulsants; Barium; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Signa | 2005 |
Successful treatment of epilepsy with serotonin reuptake inhibitors: proposed mechanism.
Topics: Adolescent; Adult; Aged; Amino Acids; Citalopram; Clinical Trials as Topic; Epilepsy; Female; Fluoxe | 2006 |
Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression.
Topics: Adolescent; Child; Child, Preschool; Depression; Epilepsy; Female; Fluoxetine; Humans; Male; Neurolo | 2007 |
Localization of the serotonergic terminal fields modulating seizures in the genetically epilepsy-prone rat.
Topics: Animals; Brain; Dihydroxytryptamines; Epilepsy; Epilepsy, Reflex; Female; Fluoxetine; Infusions, Par | 2007 |
Anticonvulsant effect of fluoxetine in humans.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Fluoxetine; Humans; Male; Middle Aged | 1995 |
Role of serotonin in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats.
Topics: 5-Hydroxytryptophan; Animals; Anticonvulsants; Epilepsy; Female; Fenclonine; Fluoxetine; Hydroxyindo | 1994 |
Lack of potentiation of anticonvulsant effect by fluoxetine in drug-resistant epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Depressive Disorder; Dose-Response Relationship, Drug; Drug Ther | 1994 |
Interaction between phenytoin and fluoxetine.
Topics: Adult; Depressive Disorder; Dose-Response Relationship, Drug; Epilepsy; Fluoxetine; Humans; Male; Ph | 1994 |
Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats.
Topics: 5-Hydroxytryptophan; Animals; Anticonvulsants; Disease Models, Animal; Drug Synergism; Epilepsy; Fem | 1994 |
Fluoxetine and aggressive behaviour.
Topics: Adult; Aggression; Epilepsy; Fluoxetine; Humans; Intellectual Disability; Selective Serotonin Reupta | 1996 |
Tryptophan and epilepsy.
Topics: Anticonvulsants; Blood-Brain Barrier; Brain; Epilepsy; Fluoxetine; Humans; Selective Serotonin Reupt | 1996 |
Fluoxetine and aggression.
Topics: Aggression; Animals; Behavior, Animal; Epilepsy; Fluoxetine; Humans; Intellectual Disability; Rats | 1997 |
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.
Topics: 1-Naphthylamine; Adult; Aged; Ambulatory Care; Anxiety Disorders; Bupropion; Depressive Disorder; Dr | 1997 |
Anticonvulsant effect of enhancement of noradrenergic transmission in the superior colliculus in genetically epilepsy-prone rats (GEPRs): a microinjection study.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Anti | 1998 |
Endogenous serotonin inhibits epileptiform activity in rat hippocampal CA1 neurons via 5-hydroxytryptamine1A receptor activation.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Barium; Epilepsy; Excitatory Postsynaptic Potential | 1998 |
Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells.
Topics: Action Potentials; Animals; Anticonvulsants; Antidepressive Agents, Second-Generation; Calcium Chann | 2000 |
[SIADH with epileptic seizures and coma in fluoxetine therapy].
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Coma; Depressive Disorder; Electr | 2000 |
Decrease of valproic acid concentration in the blood when coprescribed with fluoxetine.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Antidepressive Agents, Second-Generation; Depressive Disor | 1997 |
Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports.
Topics: Aged; Aged, 80 and over; Depressive Disorder; Drug Therapy, Combination; Epilepsy; Female; Fluoxetin | 1992 |
Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats.
Topics: Animals; Brain; Dialysis; Epilepsy; Female; Fluoxetine; Male; Rats; Seizures; Serotonin; Thalamus | 1992 |
Alteration of neocortical activity in response to noxious stimulation: participation of the dorsal raphe.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Baclofen; Cerebral Cortex; Cortical Synchronization | 1991 |